| 证券代码 | IPCI.O |
| 证券名称 | Intellipharmaceutics International Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2009-10-22 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Intellipharmaceutics International Inc. |
| 注册地址 | 30 Worcester Road, Toronto, Ontario, Canada |
| 办公地址 | 30 Worcester Road, Toronto, Ontario, Canada |
| 成立日期 | 2009-10-22 |
| 董事会主席 | Isa Odidi |
| 公司属地 | Canada 加拿大 |
| 公司网址 | www.intellipharmaceutics.com |
| 电话 | +1 (416) 798-3001 |
| 传真 | +1 (416) 798-3007 |
| 公司简介 | Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Their patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, they have developed several drug delivery systems and a pipeline of products (some of which have received FDA approval) and product candidates in various stages of development, including ANDAs filed with the FDA (and one ANDS filed with Health Canada) and one NDA filing, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (“GIT”), diabetes and pain. |